【东诚药业：贝米肝素钠注射液上市申请获受理】东诚药业公告，2026年9月9日，公司全资子公司烟台东诚北方制药有限公司收到国家药品监督管理局核准签发的贝米肝素钠注射液上市许可申请《受理通知书》，申请事项为境内生产药品注册上市许可，规格0.2ml:3500AⅩaIU，受理号CYHS2602247，决定予以受理。该产品国内仅原研上市，无仿制药上市，2025年国内全终端医院销售额为3亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.